[抗体药物偶联物在晚期非小细胞肺癌中的研究进展]
[Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer].
作者信息
Wang Na, Zhao Lu, Zhang Dou, Jia Yingjie, Kong Fanming
机构信息
Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine; National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300193, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2022 Mar 20;25(3):214-218. doi: 10.3779/j.issn.1009-3419.2022.102.01.
Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Non-small cell lung cancer (NSCLC) is one of the most important pathological types of lung cancer. The prognosis of advanced NSCLC is poor and medical treatment is still the main treatment option. Antibody-drug conjugates (ADCs) are the kind of potentially new anti-tumor drugs, consisting of monoclonal antibodies conjugated to the cytotoxic payloads via the synthetic linkers. They have a broad application prospect in solid tumors such as lung cancer. This article focuses on the mechanism of action and research progress of ADCs in advanced NSCLC. .
肺癌是全球发病率和死亡率最高的恶性肿瘤之一。非小细胞肺癌（NSCLC）是肺癌最重要的病理类型之一。晚期NSCLC的预后较差，药物治疗仍然是主要的治疗选择。抗体药物偶联物（ADCs）是一类具有潜在应用前景的新型抗肿瘤药物，由单克隆抗体通过合成连接子与细胞毒性药物连接而成。它们在肺癌等实体瘤中具有广阔的应用前景。本文重点阐述了ADCs在晚期NSCLC中的作用机制及研究进展。
Zotero 插件